spacer
home > ebr > spring 2019 > the authenticity of synthetics
PUBLICATIONS
European Biopharmaceutical Review

The Authenticity of Synthetics

Synthetic biology is a newly coined term for the design and construction of novel artificial biological pathways, organisms, or devices or the redesign of existing natural biological systems (1). Generally, it assumes an element of scale and the application of engineering-like techniques to solve biological problems through a rational process of ‘biodesign’. The field of synthetic biology brings together skills from biology and chemistry to computing, bioinformatics, and engineering. This emerging field is greatly anticipated to deliver significant and broad impact across a range of potential applications, among them the drug discovery and development field. However, to achieve its full potential, synthetic biology will require the continued development and convergence of its underlying skills and disciplines to enable the rational and predictable design of biological systems. As DNA is a fundamental building block of synthetic biology, the key to its success will be the ability to synthesise DNA at scale and with high accuracy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Tim Brears is CEO at Evonetix, where he leads the company in developing a benchtop DNA writer to transition DNA synthesis from a service industry to one where scientists can make genes at will. He holds a PhD from the University of Cambridge, UK, and has an MBA from Duke University’s Fuqua School of Business, US.
spacer
Dr Tim Brears
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm’s CSO and University of Reading Professor co-author new book on dermal formulation development

MedPharm’s Chief Scientific Officer and Co-Founder, Professor Marc Brown and University of Reading’s Professor Adrian Williams have co-authored the new book: ‘The Art and Science of Dermal Formulation Development”. It is the latest addition to ‘Drugs and the Pharmaceutical Sciences’, a series of textbooks and monographs published by CRC Press.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 2nd Quarter 2014

Synergy Research Group

The Ministry of Health of Russian Federation approved 194 new clinical trials of all types including local and bioequivalence studies during the 2nd Quarter of 2014 (3% less than at the same period of the last year). The main contribution to the total number of studies was made by multinational multi-center clinical trials (MMCT) and the number of these studies stayed the same as in Q2 2013 – 81 studies. The number of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to 59 in Q2 2014, a 22% decrease from last year’s figure. The number of local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical trials in Q2 2014.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement